Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Tetraploidization 100%
• Gefitinib Resistance 100%
• Losmapimod 100%
• Gefitinib 60%
• Epidermal Growth Factor Receptor 60%
• Genomic Instability 40%
• Activating mutation 40%
• P38 Mitogen-activated Protein Kinase (p38 MAPK) 40%
• Clinical Efficacy 20%
• Erlotinib 20%
• Signaling Pathway 20%
• Drug Resistance Reversal 20%
• Multidrug Resistance 20%
• Acquired Resistance 20%
• EGFR mutation 20%
• Cancer Cell Growth 20%
• Tumor Heterogeneity 20%
• Knockdown 20%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 20%
• Polyploidization 20%
• Point mutation 20%
• Short Hairpin RNA (shRNA) 20%
• MAPK Inhibitors 20%
• Progression-free Survival 20%
• Constitutively Active 20%
• In-frame Deletion 20%
• SB203580 20%
• Mouse Xenograft Model 20%
• Asymmetric Cell Division 20%
• Transient Phase 20%
• Cancer Hallmarks 20%
• MKK3 20%
• Exon 21 20%
• Exon 19 20%
• STAT3 Signaling 20%
• Tetraploidy 20%
• Treatment Agent 20%
• Chromosomal Loss 20%
• Tetraploid Cells 20%
• L858R 20%
• Patient's Will 20%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Gefitinib 100%
• Losmapimod 100%
• Epidermal Growth Factor Receptor 50%
• p38 Mitogen-Activated Protein Kinase 37%
• Genomic Instability 25%
• Tetraploidy 25%
• Exon 25%
• Malignant Neoplasm 12%
• Cancer Growth 12%
• Xenograft 12%
• Erlotinib 12%
• Short Hairpin RNA 12%
• Progression Free Survival 12%
• Point Mutation 12%
• Multidrug Resistance 12%
• Chromosome Loss 12%
• SB 203580 12%
• Epidermal Growth Factor Receptor Kinase Inhibitor 12%
• Asymmetric Cell Division 12%
• Polyploidy 12%
• Tumour Heterogeneity 12%
• Signal Transduction 12%
• Drug Resistance 12%

Biochemistry, Genetics and Molecular Biology

• Gefitinib 100%
• Epidermal Growth Factor Receptor 62%
• P38 Mitogen-Activated Protein Kinases 37%
• Genome Instability 25%
• Exon 25%
• Tetraploidy 25%
• Signal Transduction 12%
• Mouse Model 12%
• Polyploid 12%
• In Vivo Study 12%
• Cancer Cell 12%
• STAT3 12%
• Erlotinib 12%
• Point Mutation 12%
• Chromosome Loss 12%
• Progression Free Survival 12%
• Receptor Tyrosine Kinase Inhibitors 12%
• Multidrug Resistance 12%
• Asymmetric Cell Division 12%
• Cell Growth 12%
• Small Hairpin RNA 12%
• Drug Resistance 12%